RXi Pharmaceuticals Corp (RXII) is Resumed by H.C. Wainwright to Buy, Price Target at $3.50

RXi Pharmaceuticals Corp (RXII) was Resumed by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $3.50. H.C. Wainwright advised their investors in a research report released on Jun 7, 2016.

RXi Pharmaceuticals Corp closed down -0.01 points or -0.46% at $2.17 with 20,196 shares getting traded on Friday. Post opening the session at $2.1726, the shares hit an intraday low of $2.16 and an intraday high of $2.19 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on Apr 2, 2015, Geert Cauwenbergh (CEO) purchased 5,000 shares at $0.72 per share price. According to the SEC, on Jan 23, 2015, Robert J Bitterman (director) purchased 5,000 shares at $1.20 per share price.

RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs primarily in the areas of dermatology and ophthalmology. The Company’s development programs are based on its siRNA technology and immunotherapy agents. Its clinical development programs include self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring and an immunodulating agent Samcyprone for the treatment of such disorders as alopecia areata warts and cutaneous metastases of melanoma. In addition to these clinical programs the Company has a pipeline of discovery and preclinical product candidates in its core therapeutic areas as well as in other areas of interest.

RXi Pharmaceuticals Corp

Leave a Reply

RXi Pharmaceuticals Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on RXi Pharmaceuticals Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.